623564-30-7

Basic information

• Product Name: 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE
• Synonyms: 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE;6,7-DIHYDRO-4H-THIENO[3,2-C]PYRIDINE-2,5-DICARBOXYLIC ACID 5-TERT-BUTYL ESTER 2-ETHYL ESTER;6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLIC ACID 5-(1,1-DIMETHYLETHYL) 2-ETHYL ESTER;Ethyl 5-Boc-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carboxylate;5-tert-butyl 2-ethyl 6,7-dihydrothieno[3,2-c]pyridine-2,5(4H)-di;6,7-Dihydro-4H-thiazolo[5,4-c]pyridine-2,5-dicarboxylic acid 5-tert-butyl ester 2-ethyl ester;5-tert-butyl 2-ethyl 4H,5H,6H,7H-thieno[3,2- c]pyridine-2,5-dicarboxylate;5-tert-butyl 2-ethyl 6,7-dihydro-1H-pyrrolo[3,2-c]pyridine-2,5(4H)-dicarboxylate
• CAS NO: 623564-30-7
• Molecular Formula: C₁₅H₂₁NO₄S
• Molecular Weight: 311.4
• Mol File: 623564-30-7.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE(623564-30-7)
• EPA Substance Registry System: 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE(623564-30-7)

Safety Data

• Hazardous Substances Data: 623564-30-7(Hazardous Substances Data)

Usage

General Description

5-Tert-butyl 2-ethyl 6,7-dihydrothieno[3,2-c]pyridine-2,5(4H)-dicarboxylate is a chemical compound with the molecular formula C22H29NO4S. It is a dihydropyridine derivative that is commonly used in the pharmaceutical industry for its potential therapeutic properties. 5-TERT-BUTYL 2-ETHYL 6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-2,5(4H)-DICARBOXYLATE is known for its ability to act as a calcium channel blocker, which means it can help relax and widen the blood vessels, leading to improved blood flow and reduced blood pressure. It is also being studied for its potential use in treating conditions such as hypertension and angina. Additionally, it is known for its lipophilic nature, meaning it has a high affinity for fatty substances, which could potentially impact its pharmacokinetic and pharmacodynamic properties.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 623-51-8 ethyl 2-sulfanylacetate 
• 1190971-25-5 benzyl 4-chloro-3-formyl-5,6-dihydropyridine-1(2H)-carboxylate 
• 230301-73-2 6,7-dihydro-4H-thieno[3,2-c]-pyridine-5-carboxylic acid tert-butyl ester 
• 541-41-3 chloroformic acid ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1190971-27-7 5-benzyl 2-ethyl 6,7-dihydrothieno[3,2-c]pyridine-2,5(4H)-dicarboxylate 
• 885275-20-7 tert-butyl 4-chloro-5-formyl-3,6-dihydropyridine-1(2H)-carboxylate 

Downstream Products

• 1190970-06-9 2-((1-(4-methoxy-2,6-dimethylphenylsulfonyl)piperidin-2-yl)methoxy)-1-(2-(piperidin-1-ylmethyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanone 
• 1190970-43-4 2-[[(2S)-1-[(4-methoxy-2,6-dimethyl-phenyl)sulfonyl]-piperidin-2-yl]-methoxy]-1-[2-(pyrrolidin-1-yl-methyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-ethanone 
• 1190970-05-8 (R)-N-(3-oxo-1-phenyl-3-(2-(piperidin-1-ylmethyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)propyl)naphthalene-2-sulfonamide 
• 1190970-07-0 4-methoxy-N,2,6-trimethyl-N-(2-(2-oxo-2-(2-(piperidin-1-ylmethyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethoxy)ethyl)benzenesulfonamide 
• 1190970-37-6 N-[2-[2-[2-(azetidin-1-yl-methyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridin-5-yl]-2-oxo-ethoxy]-ethyl]-2-chloro-N-cyclopropyl-6-methyl-benzenesulfonic acid amide 

Relevant articles and documents

Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation

Protein arginine methyltransferases 5 (PRMT5) represents an attractive drug target in epigenetic field for the treatment of leukemia and lymphoma. Here, a series of N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)amide derivatives targeting PRMT5 were designed with structure-based approach and synthesized. Among them, compound 46 showed potent and selective PRMT5 inhibition activity with an IC50 of 8.5 nM, which was approximately equivalent with the phase I clinical trial PRMT5 inhibitor GSK-3326595 (IC50 = 5.5 nM). Compound 46 also displayed pronounced anti-proliferative activity in MV4-11 cells (GI50 = 18 nM) and antitumor activity in MV4-11 mouse xenografts model. This molecule can serve as an excellent tool compound for probing the biological function of PRMT5.

CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.